Chemotherapy induced nausea and vomiting product available for in-licensing
Polysorbate free 505(b)(2) product available for in-licensing in the US market. Advantages over other comparable products include favorable side effect profile and ready to use solution.
Market research conducted with hospital pharmacists and chemotherapy clinics indicate that the product will be accepted in the marketplace upon approval.
.
https://commercialhealthcarepartners.com/wp-content/uploads/2021/10/505-icon.png
300
300
Jim Usry
https://commercialhealthcarepartners.com/wp-content/uploads/2021/10/CHP-logo-2021_blu-790x350-2.png
Jim Usry2021-10-26 15:52:272021-10-31 18:41:20505(b)(2) formulation for chemotherapy available in-licensing
https://commercialhealthcarepartners.com/wp-content/uploads/2021/10/505-icon.png
300
300
Jim Usry
https://commercialhealthcarepartners.com/wp-content/uploads/2021/10/CHP-logo-2021_blu-790x350-2.png
Jim Usry2021-10-26 15:47:292021-10-31 18:41:41505(b)(2) formulation for schizophrenia available in-licensing
https://commercialhealthcarepartners.com/wp-content/uploads/2021/10/505-icon.png
300
300
Jim Usry
https://commercialhealthcarepartners.com/wp-content/uploads/2021/10/CHP-logo-2021_blu-790x350-2.png
Jim Usry2021-08-17 15:44:022021-10-31 18:42:01Approved 505(b)(2) available for in-licensing
https://commercialhealthcarepartners.com/wp-content/uploads/2021/10/In-License-icon.png
300
300
Jim Usry
https://commercialhealthcarepartners.com/wp-content/uploads/2021/10/CHP-logo-2021_blu-790x350-2.png
Jim Usry2020-10-10 15:36:022021-10-31 18:07:59Chemotherapy induced nausea and vomiting product available for in-licensing
https://commercialhealthcarepartners.com/wp-content/uploads/2021/10/In-License-icon.png
300
300
Jim Usry
https://commercialhealthcarepartners.com/wp-content/uploads/2021/10/CHP-logo-2021_blu-790x350-2.png
Jim Usry2020-09-20 15:05:132021-10-31 18:08:31Schizophrenia asset available for in-licensing
